Clinical Trials in New York

Showing 4921-4940 of 22,668 trials

Engaging Black Youth in Depression and Suicide Prevention Treatment Within Urban Schools

NCT03940508

Completing evidence-based treatments for depression has been shown to be particularly problematic for Black adolescents. If Black adolescents' depression treatment needs are to be met, the engagement challenges and the factors that lessen the success of treatment in the "real world" must be addressed. The investigators will examine the effectiveness of the Making Connections Intervention (MCI) and investigate key mediators of both engagement and response to treatment for depression. The MCI is a 1-2 session, evidence-based intervention designed to improve engagement, perceived relevance, and treatment satisfaction among depressed, Black adolescents. The study also uses tailored outreach strategies for adolescents and parents by including innovative digital content such as a web page/app along with other digital products. This study will address an important public health issue: How best to connect Black adolescents with depression to treatment in clinically meaningful ways, and how best to deliver evidence-based treatment to them through school-based services.

DepressionSuicidal Ideation

New York University29 participantsStarted Jan 2020

New York, New York, United States • New York, New York, United States

COMPLETEDPhase 1/2< 1 mile

Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus

NCT02052739

The purpose of this study is to evaluate the safety and tolerability of SAGE-547 in participants in super-refractory status epilepticus (SRSE).

Super-refractory Status Epilepticus

Supernus Pharmaceuticals, Inc.25 participantsStarted Mar 2014

Birmingham, Alabama, United States • Sarasota, Florida, United States • Chicago, Illinois, United States +14 more locations

Engaging Black Youth in Depression and Suicide Prevention Treatment Within Urban Schools

Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus

Find Trials by Condition in New York

Tailored vs. Anatomical Ablation Strategy for Persistent Atrial Fibrillation

Evaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma.

A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy

OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages

A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease

Periprosthetic Fracture Registry (PPFx)

Development/Testing of SUMMIT: a Tool to Help Patients Manage Pain While Tapering Opioids

Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)

Pharmacodynamic EffIcacy and Clinical Benefit of AT 007 in Patients With Sorbitol Dehydrogenase (SORD) Deficiency

NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)

A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)

Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors

A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer

Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With Phenylketonuria

First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

SPRINT: Signature for Pain Recovery IN Teens

A Study in Adults to Investigate the Impact of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Venglustat Compared to Participants With Normal Hepatic Function

A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)